Walsall

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Researchers are studying the use of ruxolitinib cream in children aged 6 to under 12 years who have nonsegmental vitiligo. The study aims to evaluate how well and how safely the cream works for treating this condition, which causes loss of skin color. This is a Phase 3 clinical trial focused on treatment effects in this pediatric population. Participants are assigned to one of three groups receiving either ruxolitinib cream at 0.75% or 1.5%, or a matching vehicle placebo cream. Each cream is applied topically as a thin film twice daily to the affected skin areas as defined in the study protocol. The treatment period lasts up to 24 weeks, during which changes in skin pigmentation are monitored. Throughout the study, participants undergo regular assessments including evaluations of vitiligo improvement on the face and body using the Vitiligo Area Scoring Index and other scales. Safety is monitored by tracking adverse events and blood levels of the drug at multiple timepoints up to 52 weeks. Quality of life and psychosocial effects are also measured. The total study duration includes treatment and follow-up visits to assess long-term outcomes and safety.

Researchers are evaluating the efficacy and safety of tulisokibart in participants with moderately to severely active Crohns disease. This program includes two studies Study 1 involves both induction and maintenance treatment phases, while Study 2 focuses only on induction treatment. The main goal is to determine if one or more doses of tulisokibart are more effective than placebo in achieving clinical remission and endoscopic response at various time points up to Week 52. Participants are randomly assigned to receive different dosing regimens of tulisokibart or placebo. These regimens include high or low doses administered intravenously followed by subcutaneous injections, or subcutaneous injections alone. Some participants may continue in an extension phase receiving subcutaneous doses after completing their original treatment arm if they meet specific requirements. The studies use a double-blind design to compare tulisokibarts effects against placebo. During the trial, participants undergo regular assessments to measure clinical remission, endoscopic response, and other health outcomes using tools like the Crohns Disease Activity Index and stool frequency with abdominal pain scores. Safety evaluations include monitoring adverse events and treatment discontinuations. The studies last up to 52 weeks for Study 1 and 12 weeks for Study 2, with multiple visits to assess treatment effects and participant health under medical supervision.

Researchers are evaluating the Heartfelt device, a new passive monitoring system that detects early signs of fluid build-up in patients with heart failure by measuring changes in foot and lower leg volume using 3D images. The study aims to see if adding this device to standard NHS care improves quality of life and reduces heart failure-related events compared to standard care alone. The trial involves 300 participants from multiple NHS hospitals and GP practices across the UK and uses a randomized crossover design. Participants will be randomly assigned to receive either standard NHS care, which includes regular weight checks and symptom monitoring, or standard care plus the Heartfelt device installed at home. The device captures daily images of the feet to track swelling without extra effort from the user. Alerts triggered by important changes are sent to the clinical team for prompt action. Both groups receive a patient booklet from the British Heart Foundation to support self-monitoring and understanding of heart failure. During the study, participants quality of life will be assessed using questionnaires at baseline and at 3, 6, 9, and 12 months. The study will also monitor hospitalizations, deaths, medication adherence, and the availability of daily device data. Researchers will evaluate how the clinical teams respond to alerts, the ease of device use, and its cost-effectiveness. The total participation period covers 12 months of monitoring and data collection.

Researchers are evaluating a new blood test called Avantect to detect pancreatic cancer early in people aged 50 to 84 who were recently diagnosed with type 2 diabetes. Pancreatic cancer is often deadly because it is usually found late. This study aims to see if the Avantect test can find signs of cancer sooner, allowing for earlier treatment and better chances of survival. The study is interventional and includes a large group of participants recruited from general practices over three years. Participants will be randomly assigned to one of two groups the intervention arm or the control arm. Those in the intervention arm will have their blood samples tested with the Avantect test quickly, and if cancer markers are found, they will be informed and offered imaging scans like MRI or CT to check for pancreatic cancer. The control group will have their blood samples stored for possible future testing but will receive standard diabetes care. Blood samples and health outcomes will be tracked for three years. Each participant will attend three study visits over 12 months, providing blood samples and completing anxiety questionnaires. Researchers will monitor cancer diagnosis and mortality through registries for three years after consent. They will evaluate the tests sensitivity, specificity, and ability to detect cancer early enough for surgery. The study also measures predictive values and cancer resectability. This design helps understand the tests potential to improve pancreatic cancer detection in people with new diabetes diagnoses.

Aortic stenosis AS affects many older adults, with a rising number of people over 65 and 75 years old experiencing moderate to severe disease. This study aims to compare the benefits of early aortic valve replacement AVR versus expectant management in patients with severe asymptomatic AS. It addresses a significant gap, as no randomized controlled trials have yet compared these approaches to determine which leads to better outcomes and cost-effectiveness. Participants will be randomly assigned to either early AVR, where surgery or transcatheter AVR TAVI is planned within six months, or to expectant management, involving regular monitoring according to standard hospital practice. The study will be conducted across multiple centers in the UK, Australia, and New Zealand, with an internal pilot phase to confirm recruitment feasibility. Those in the AVR group may undergo additional tests such as coronary angiography, with further treatment decisions made by their care team. During the study, participants will be followed for a median of 5.5 years, with assessments including cardiovascular events, hospitalizations, quality of life questionnaires, and health economics evaluations. Researchers will measure a combined outcome of cardiovascular death, heart failure hospitalization, and stroke, along with other health and disability measures. The study will use intention-to-treat analysis, ensuring participants are evaluated in their assigned groups regardless of treatment received.

The trial investigates whether stopping or continuing milk feeding around the time of blood transfusion in very premature infants born before 30 weeks gestation affects the risk of developing Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can cause severe damage or death in preterm infants, and this study aims to find out which feeding approach during transfusion may reduce this risk. The trial is conducted in neonatal intensive care units across Canada and the UK and compares two standard care methods currently in use. Participants are randomly assigned to one of two groups one group will stop all enteral feeds for 4 hours before, during, and 4 hours after packed red cell transfusions, with hydration maintained by intravenous nutrition or glucose the other group will continue feeding as usual throughout the transfusion period. Infants stay in their assigned feeding group until they reach 34 weeks and 6 days gestational age. This approach follows practices identified as acceptable in prior surveys and studies. During the study, infants will be closely monitored for the development of NEC and other health outcomes from randomization until 40 weeks postmenstrual age. Researchers will track serious complications like severe NEC, infections, growth, lung disease, eye problems, brain injury, and hospital stay duration. The study collects detailed information about feeding, infections, nutrition, and clinical status to evaluate the safety and effects of each feeding strategy during transfusion.